What is claimed is:

1. A method comprising:

~~obtaining a biological sample from a subject;~~

analyzing ~~the~~ a biological sample obtained from a subject for a biomarker anti-β-glucan antibody compared to a reference standard;

computing a Relative Antibody Unit (RAU) value for anti-β-glucan antibody in the sample; and

identifying the subject as biomarker ~~positive~~ negative for β-glucan immunotherapy if the RAU value is ~~greater~~ less than a predetermined RAU value for the biomarker anti-β-glucan antibody, wherein the predetermined RAU value is selected based on a correlation of specificity and sensitivity to at least one endpoint that stratifies biomarker-positive subjects and biomarker-negative subjects, and

wherein anti-β-glucan IgG_2 is to be administered to the biomarker-negative subject.

2. A method comprising:

~~obtaining a biological sample from a subject;~~

analyzing ~~the~~ a biological sample obtained from a subject for a biomarker anti-β-glucan antibody compared to a reference standard; ~~and~~

identifying the subject as biomarker ~~positive~~ negative for β-glucan immunotherapy if the sample contains an amount of the anti-β-glucan antibody that is ~~greater~~ less than a predetermined cutoff value for the biomarker anti-β-glucan antibody, wherein the predetermined cutoff value is selected based on a correlation of specificity and sensitivity to at least one endpoint that ~~separates~~ stratifies biomarker-positive subjects from biomarker-negative subjects, and

wherein anti-β-glucan IgG_2 is to be administered to the biomarker-negative subject.

3. The method of claim 1 ~~or claim 2~~ wherein the biomarker anti-β-glucan antibody comprises IgG.

4. The method of claim 1 wherein the biomarker anti-β-glucan antibody comprises IgG and the predetermined RAU value is 200.

5. The method of claim 1 ~~or claim 2~~ wherein the biomarker anti-β-glucan antibody comprises IgM.

6. The method of claim 1 wherein the biomarker anti-β-glucan antibody comprises IgM and the predetermined RAU value is 300.

~~7. The method of any preceding claim further comprising administering to a subject identified as biomarker positive a composition that comprises β-glucan.~~

~~8~~7. The method of claim 1 ~~any preceding claim~~ wherein the β-glucan is derived from yeast.

~~9~~8. The method of ~~any preceding claim~~claim 1 wherein the β-glucan comprises a β-1,3/1,6 glucan.

~~10~~9. The method of ~~any preceding claim~~ claim 1 wherein the β-glucan comprises β(1,6)-[poly-(1,3)-D-glucopyranosyl]-poly-β(1,3)-D-glucopyranose.

~~11~~10. The method of ~~any preceding claim~~claim 1 wherein the sample is analyzed for a biomarker anti-β-glucan antibody using an enzyme-linked immunosorbent assay (ELISA).

~~12~~11. The method of claim 1 wherein the endpoint comprises clinical outcomes, binding to immune cells, activation of complement components, modulation of immune cell surface marker expression or induction of cytokines. ~~any preceding claim wherein the method further includes administering to the subject a composition that comprises anti-β-glucan IgG_2.~~

12. The method of claim 1 wherein the predetermined cutoff value is about 20 µg/ml anti--β-glucan IgG.

13. The method of claim 2 wherein the biomarker anti-β-glucan antibody comprises IgG.

14. The method of claim 2 wherein the biomarker anti--β-glucan antibody comprises IgM.

15. The method of claim 2 wherein the β-glucan is derived from yeast.

16. The method of claim 2 wherein the β-glucan comprises a β-1,3/1,6 glucan.

17. The method of claim 2 wherein the β-glucan comprises β(1,6)-[poly-(1,3)-D-glucopyranosyl]-poly-β(1,3)-D-glucopyranose.

18. The method of claim 2 wherein the sample is analyzed for a biomarker anti β-glucan antibody using an enzyme-linked immunosorbent assay (ELISA).

19. The method of claim 2 wherein the endpoint comprises clinical outcomes, binding to immune cells, activation of complement components, modulation of immune cell surface marker expression or induction of cytokines.

20. The method of claim 2 wherein the predetermined cutoff value is about 20 µg/ml anti--β-glucan IgG.